Increased T-cell responses that control bovine leukemia virus proviral load in beef cattle under dietary vitamin A restriction for marbling

Author(s):  
Sonoko Miyauchi ◽  
Yuzuru Katagiri ◽  
Chihiro Ochiai ◽  
Toh-ichi Hirata ◽  
Keiichi Matsuda ◽  
...  
2016 ◽  
Vol 137 (2) ◽  
pp. AB407
Author(s):  
Stefanie Wagner ◽  
Karin Hufnagl ◽  
Luis F.F. Pacios ◽  
Franziska Roth-Walter ◽  
Rodolfo Bianchini ◽  
...  

Virology ◽  
2006 ◽  
Vol 349 (1) ◽  
pp. 142-155 ◽  
Author(s):  
Vladimir A. Novitsky ◽  
Peter B. Gilbert ◽  
Kimberly Shea ◽  
Mary F. McLane ◽  
Natasha Rybak ◽  
...  

2004 ◽  
Vol 78 (12) ◽  
pp. 6322-6334 ◽  
Author(s):  
Daisuke Sugahara ◽  
Sachiyo Tsuji-Kawahara ◽  
Masaaki Miyazawa

ABSTRACT Recent studies have demonstrated an essential role of Gag-specific CD4+ T-cell responses for viral control in individuals infected with human immunodeficiency virus type 1. However, little is known about epitope specificities and functional roles of the Gag-specific helper T-cell responses in terms of vaccine-induced protection against a pathogenic retroviral challenge. We have previously demonstrated that immunization with Friend murine leukemia virus (F-MuLV) Gag proteins protects mice against the fatal Friend retrovirus (FV) infection. We report here the structure of a protective T helper cell (Th) epitope, (I)VTWEAIAVDPPP, identified in the p15 (MA) region of F-MuLV Gag. In mice immunized with the Th epitope-harboring peptide or a vaccinia virus-expressed native full-length MA protein, FV-induced early splenomegaly regressed rapidly. In these mice, FV-infected cells were eliminated within 4 weeks and the production of virus-neutralizing antibodies was induced rapidly after FV challenge, resulting in strong protection against the virus infection. Interestingly, mice immunized with the whole MA mounted strong CD4+ T-cell responses to the identified Th epitope, whereas mice immunized with mutant MA proteins that were not bound to the plasma membrane failed to mount efficient CD4+ T-cell responses, despite the presence of the Th epitope. These mutant MA proteins also failed to induce strong protection against FV challenge. These data indicate the importance of the properly processible MA molecule for CD4+ T-cell priming and for the resultant induction of an effective immune response against retrovirus infections.


Blood ◽  
2003 ◽  
Vol 101 (8) ◽  
pp. 3074-3081 ◽  
Author(s):  
Ryuji Kubota ◽  
Yoshitaka Furukawa ◽  
Shuji Izumo ◽  
Koichiro Usuku ◽  
Mitsuhiro Osame

AbstractHuman T-lymphotropic virus type 1 (HTLV-1)–associated myelopathy/tropical spastic paraparesis (HAM/TSP) is an inflammatory neurologic disease caused by HTLV-1 infection, in which HTLV-1–infected CD4+ T cells and HTLV-1–specific CD8+ T cells may play a role in the disease pathogenesis. Patients with HAM/TSP have high proviral loads despite vigorous virus-specific CD8+ T-cell responses; however, it is unknown whether the T cells are efficient in eliminating the virus in vivo. To define the dynamics of HTLV-1–specific CD8+T-cell responses, we investigated longitudinal alterations in HTLV-1 proviral load, amino acid changes in an immunodominant viral epitope, frequency of HTLV-1–specific T cells, and degeneracy of T-cell recognition in patients with HAM/TSP. We showed that the frequency and the degeneracy of the HTLV-1–specific CD8+ T cells correlated well with proviral load in the longitudinal study. The proviral load was much higher in a patient with low degeneracy of HTLV-1–specific T cells compared to that in a patient with comparable frequency but higher degeneracy of the T cells. Furthermore, in a larger number of patients divided into 2 groups by the proviral load, those with high proviral load had lower degeneracy of T-cell recognition than those with low proviral load. Sequencing analysis revealed that epitope mutations were remarkably increased in a patient when the frequency and the degeneracy were at the lowest. These data suggest that HTLV-1–specific CD8+ T cells with degenerate specificity are increased during viral replication and control the viral infection.


2015 ◽  
Vol 75 (4) ◽  
pp. 656-665 ◽  
Author(s):  
Yuan Hong ◽  
Indumathi Manoharan ◽  
Amol Suryawanshi ◽  
Tanmay Majumdar ◽  
Melinda L. Angus-Hill ◽  
...  

2009 ◽  
Vol 84 (4) ◽  
pp. 1967-1976 ◽  
Author(s):  
Wibke Bayer ◽  
Matthias Tenbusch ◽  
Ruth Lietz ◽  
Lena Johrden ◽  
Simone Schimmer ◽  
...  

ABSTRACT We present a new type of adenoviral vector that both encodes and displays a vaccine antigen on the capsid, thus combining in itself gene-based and protein vaccination; this vector resulted in an improved vaccination outcome in the Friend virus (FV) model. For presentation of the envelope protein gp70 of Friend murine leukemia virus on the adenoviral capsid, gp70 was fused to the adenovirus capsid protein IX. When compared to vaccination with conventional FV Env- and Gag-encoding adenoviral vectors, vaccination with the adenoviral vector that encodes and displays pIX-gp70 combined with an FV Gag-encoding vector resulted in significantly improved protection against systemic FV challenge infection, with highly controlled viral loads in plasma and spleen. This improved protection correlated with improved neutralizing antibody titers and stronger CD4+ T-cell responses. Using a vector that displays gp70 without encoding it, we found that while the antigen display on the capsid alone was sufficient to induce high levels of binding antibodies, in vivo expression was necessary for the induction of neutralizing antibodies. This new type of adenovirus-based vaccine could be a valuable tool for vaccination.


Sign in / Sign up

Export Citation Format

Share Document